100s of titles, one news app for just $10 a month.
Dive Deeper:
Infinity Pharmaceuticals's Return On Capital Employed Insights
Benzinga Pro data, Infinity Pharmaceuticals (NASDAQ:INFI) reported Q1 sales of $652.00 thousand. Earnings fell to a loss of $12.44 million,…
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
One subscription that gives you access to news from hundreds of sites
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
Get all your news in one place
Latest Business news:
Wage growth likely way behind inflation
New figures are likely to show wages were growing at an annual rate of 2.5 per cent as of the…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Markets rally eyeing China reopening
London (AFP) - Global stock markets rallied Tuesday on hopes that China will ease its weeks-long Covid lockdown and gradually…
Netflix Lays Off 150 Staffers in Cutback After Subscriber Loss
Netflix  Inc. said Tuesday it’s laying off about 150 employees, fallout from the surprising drop in customers the streaming company…
Will social media companies crack down on the racist conspiracy theory behind the Buffalo massacre?
The Buffalo, New York, mass shooting that claimed 10 lives Saturday was an event shaped by, and for, internet platforms,…
The Indian economy is being rewired. The opportunity is immense
And so are the stakes
From analysis to good news, read the world’s best news in one place
Bucking the trend: Is there a future for ultra-long-haul flights in a net-zero carbon world?
As the world gets more serious about climate action, long-haul flights such as those introduced by Qantas will come under…
Coinbase Responds to Crypto Rout
The crypto trading platform had planned to triple its employee headcount, but suspended hiring as its stock fell sharply.

Rhythm Pharmaceuticals's Return On Capital Employed Insights

By Benzinga Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million. Rhythm Pharmaceuticals collected $1.82 million in revenue during Q4, but reported earnings showed a $42.87 million loss.

What Is ROCE?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Rhythm Pharmaceuticals posted an ROCE of -0.22%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Rhythm Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Rhythm Pharmaceuticals, a negative ROCE ratio of -0.22% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Rhythm Pharmaceuticals reported Q1 earnings per share at $-1.05/share, which did not meet analyst predictions of $-1.01/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Infinity Pharmaceuticals's Return On Capital Employed Insights
Benzinga Pro data, Infinity Pharmaceuticals (NASDAQ:INFI) reported Q1 sales of $652.00 thousand. Earnings fell to a loss of $12.44 million,…
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
One subscription that gives you access to news from hundreds of sites
Apollo Endosurgery's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase…
Kymera Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million,…
Get all your news in one place